RESUMEN
Adults with relapsed/refractory acute lymphoblastic leukemia have a poor prognosis. While current immunotherapies are promising, they are toxic, with graft-versus-host disease a major complication of allogeneic therapy. Here, we report a patient with high-risk relapsed/refractory Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (ALL) following chemotherapy induction, matched related donor allogeneic hematopoietic stem cell transplantation (allo-HCT), donor lymphocyte infusion and two tyrosine kinase inhibitors. The patient achieved a complete molecular and cytogenetic remission with minimal adverse events or evidence of GVHD following recombinant human IL-2 (rIL-2), in combination with a tyrosine kinase inhibitor (TKI). There was a ninefold increase in natural killer (NK) cell activity and natural killer T cells (NKT) cells (CD2+CD26+). Personalized low dose recombinant human IL-2-mediated NK cell stimulation represents an effective, nontoxic immunotherapy administered in the outpatient setting for relapsed acute lymphoblastic leukemia and warrants further investigation.
RESUMEN
Conversion disorder or a functional neurological symptom disorder is a psychiatric illness in which psychological conflicts are manifested as physical symptoms. Common examples of symptoms include blindness, paralysis, dystonia, anesthesia, inability to speak, difficulty swallowing, incontinence, balance problems, tremors, difficulty walking, hallucinations, and psychogenic non-epileptic seizures (PNES). Conversion disorder is often missed on initial medical and neurological evaluations due to the lack of a definitive organic diagnosis. This case highlights the presentation and diagnostic complication of a patient with conversion disorder and emphasizes the importance of implementing a multidisciplinary approach to the treatment of this disorder, including clinician-patient proper communication, proper neurological/epilepsy evaluation, psychiatric therapy, psychotherapy, physical therapy, and pharmacotherapy.